Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.

The production method for absorbing at least one composition in the intestine with a high amount so that it is carried to the target tissues in a healthy way, wherein the composition contains at least one bioactive molecule and at least one carrier, has the steps of reducing the carrier to the nanosize, preparing the bioactive molecule so that it can be loaded on the nano-sized carrier, and loading the prepared bioactive molecule onto the nano-sized carrier is disclosed. Many bioactive molecules, especially curcumin, can be carried to target tissues in the living organism by using a nanocarrier. It can also be used in all sectors for carrying molecular structures at nanosize.

The production method for absorbing at least one composition in the intestine with a high amount so that it is carried to the target tissues in a healthy way, wherein the composition contains at least one bioactive molecule and at least one carrier, has the steps of reducing the carrier to the nanosize, preparing the bioactive molecule so that it can be loaded on the nano-sized carrier, and loading the prepared bioactive molecule onto the nano-sized carrier is disclosed. Many bioactive molecules, especially curcumin, can be carried to target tissues in the living organism by using a nanocarrier. It can also be used in all sectors for carrying molecular structures at nanosize.

A method for screening compounds and compositions that reduce cetyl pyridinium chloride activation of TRPA1 receptor or TRPV1 receptor.

A method for screening compounds and compositions that reduce cetyl pyridinium chloride activation of TRPA1 receptor or TRPV1 receptor.

A method for screening compounds and compositions that reduce cetyl pyridinium chloride activation of TRPA1 receptor or TRPV1 receptor.

A metabolic enhancing pharmaceutical composition can include xanthohumol and curcumin, and these components can be in extract form, for example. In another example, a method of enhancing the metabolic stability of a curcumin extract in the body can include combining a curcumin extract with an extract of xanthohumol from hops.

A metabolic enhancing pharmaceutical composition can include xanthohumol and curcumin, and these components can be in extract form, for example. In another example, a method of enhancing the metabolic stability of a curcumin extract in the body can include combining a curcumin extract with an extract of xanthohumol from hops.

Embodiments of the disclosure relate to treatments for ringworm on biotic and abiotic surfaces. According to one aspect, a concentrated antimicrobial solution is provided. The concentrated solution includes an antimicrobial composition, a solubilizing agent, and an essential oil. The concentrated antimicrobial solution can be mixed with water, and the resulting solution can be used to disinfect abiotic surfaces from ringworm. According to another aspect, an antimicrobial cream is provided. The antimicrobial cream includes a carrier including a humectant and an antimicrobial composition dispersed in the carrier at 1% w/v or greater.

Embodiments of the disclosure relate to treatments for ringworm on biotic and abiotic surfaces. According to one aspect, a concentrated antimicrobial solution is provided. The concentrated solution includes an antimicrobial composition, a solubilizing agent, and an essential oil. The concentrated antimicrobial solution can be mixed with water, and the resulting solution can be used to disinfect abiotic surfaces from ringworm. According to another aspect, an antimicrobial cream is provided. The antimicrobial cream includes a carrier including a humectant and an antimicrobial composition dispersed in the carrier at 1% w/v or greater.